Britain and America have established a important bilateral deal that will preserve no import taxes on UK medicine shipments going into the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to raise spending on pharmaceuticals through the public health system. This commitment ensures that tariffs on these key exports will stay at zero for a timeframe of 36 months.
This agreement comes after previous statements to dramatically increase duties on branded drug imports, with figures discussed as high as double the cost.
"This deal with the United Kingdom bolsters the global environment for cutting-edge drugs and introduces much-needed fairness to American-British medicine commerce," a release declared.
Economic Importance
Medicines constitute one of the the United Kingdom's largest export categories to the United States, which is by far the largest buyer for leading companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period to the end of September, the UK exported pharmaceutical products worth over eleven billion pounds to the US. This amount made up 17.4% of total UK exports in that span.
"This guarantee secures jobs, increases capital expenditure and sets the stage for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary remarked.
Detailed British Pledges
The agreement involves several key commitments from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a target to raise overall NHS spending on drugs from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to control costs will be restricted at 15%. Previously, refunds were more than 20%.
Recent Tensions
This agreement comes amid a protracted row between the pharmaceutical industry and the ministers over spending levels and regulatory access.
The disagreement were heightened by assertions that American consumers were charged significantly more for the equivalent treatments than people in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been halted or abandoned, while major funding commitments have been announced toward American operations.
The Science Minister publicly accepted that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the last ten years.
